Artal Group S.A. Macrogenics Inc Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 10, 2018	SELL	$18.89 - $32.46 $1.89 Million - $3.25 Million	-100,000 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$16.19 - $20.3 $1.62 Million - $2.03 Million	-100,000 Reduced 50.0%	100,000 $1.9 Million
Q3 2017 Nov 08, 2017	BUY	$15.52 - $18.94 $3.1 Million - $3.79 Million	200,000	200,000 $3.7 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $197M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.